-+ 0.00%
-+ 0.00%
-+ 0.00%

Processa Pharmaceuticals Pres. R&D David Young acquires 1,545 shares for $4,586.65

PUBT·04/17/2026 20:55:55
Listen to the news
Processa Pharmaceuticals Pres. R&D David Young acquires 1,545 shares for $4,586.65
  • Processa Pharmaceuticals director David Young, president of research and development, bought 1,545 common shares at USD 2.97 each.
  • Direct holdings rose to 12,107 common shares.
  • Indirect holdings totaled 2,416 common shares through a revocable trust, family entities, and CorLyst, LLC.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Processa Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000897069-26-000912), on April 17, 2026, and is solely responsible for the information contained therein.